Cargando…
Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
BACKGROUND: The current study evaluated the long-term (52 week) safety and impact on symptom measures of lurasidone (with or without lithium or valproate) for the treatment of bipolar I disorder in Japanese patients. METHODS: Bipolar patients for this open-label flexibly dosed lurasidone (20–120 mg/...
Autores principales: | Higuchi, Teruhiko, Kato, Tadafumi, Miyajima, Mari, Watabe, Kei, Masuda, Takahiro, Hagi, Katsuhiko, Ishigooka, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333182/ https://www.ncbi.nlm.nih.gov/pubmed/34342746 http://dx.doi.org/10.1186/s40345-021-00230-8 |
Ejemplares similares
-
Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression
por: Kato, Tadafumi, et al.
Publicado: (2020) -
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo, Masaomi, et al.
Publicado: (2021) -
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019) -
Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
por: Miura, Itaru, et al.
Publicado: (2022) -
Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
por: Iyo, Masaomi, et al.
Publicado: (2021)